Hoth receives U.S. notice of allowance for therapy
The patent allowance covers a novel exon-skipping therapy targeting allergic diseases.
See the latest news and media coverage for Hoth. We track all announcements, press releases, and industry mentions in real time, all in one place.
Early-stage biopharmaceutical research and development company
hoththerapeutics.comLast updated
In short: Hoth advanced its HT-001 and HT-KIT programs, secured patents, adopted AI tools, and reported Q1 losses during its Rocket One rebrand.
The patent allowance covers a novel exon-skipping therapy targeting allergic diseases.
These updates focus on oncology dermatology, advancing their research pipeline.
The drug aims to treat Alzheimer's disease and associated dementia symptoms.
By deploying Lantern Pharma's platform, Hoth aims to reduce risks and accelerate timelines toward therapies.
Hoth Therapeutics stock is now tied to Rocket One's planned 100 percent acquisition of Tracer Drone Technologies, a move that shifts the former biotechnology company...
On Wednesday, Momentus (MNTS) jumped another 26% after more than doubling in the previous session,...
Hoth Therapeutics had been developing an experimental skin treatment drug, but the company was yet ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued...
Track Hoth and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Hoth and other trending companies.